Rebecsinib Clinical Trial Means New Options for Blood Cancer
Health & BehaviorA clinical trial of rebecsinib — an investigational drug that inhibits the ADAR1 gene involved in the growth of more than 20 cancers — is underway at UC San Diego.
Research
Featured Articles
The Latest
Nobel Laureate and UC San Diego Alumnus Susumu Tonegawa (1939-2026)
Health & BehaviorSusumu Tonegawa, who made key contributions to immunology and neurobiology and became UC San Diego’s first alumnus to receive a Nobel Prize, passed away on July 11. His research resolved a long-standing puzzle about how the immune system generates millions of antibodies from a small set of genes.
Mindfulness-Based Therapy for Opioid Misuse Offers Massive Return on Investment
Business & EconomicsA mindfulness-based treatment for opioid use disorder could generate $12 in economic benefit for every dollar spent, a massive improvement on current approaches.
One Month on a Vegan Diet Shifts Epigenetic Patterns Associated with Aging and Inflammation
Health & BehaviorResearchers from University of California San Diego have found that switching to a vegan diet for just one month can alter the body’s epigenetic landscape in ways associated with reduced inflammation and biological aging.
UC San Diego Students Learn Spatial Data Science Through Real-World Applications
Science & EnvironmentUC San Diego students are bridging GIS and machine learning to solve real-world challenges in public health and urban planning. In a new spatial analysis course, they analyze complex geospatial data to identify environmental risks and support smarter community decision-making.
UC San Diego Launches New Business Data Science Major
Business & EconomicsThe first program of its kind in the UC system, a new bachelor’s degree from the Halıcıoğlu School for Data Science and Computing and the Rady School of Management will enable students to turn data into strategic business decisions.
Trending Stories
Stay in the Know
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
